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2 
ABSTRACT 
 
The avenues of targeted immunotherapy offers a promise of less toxic treatment options 
for those battling different forms of cancer. Specifically, the process of hijacking a patient’s own 
immune system to fight cancer from within versus using external treatments like chemotherapy 
which is extremely damaging to the patient. One such avenue includes the usage of monoclonal 
antibodies as an effective modality for immunotherapy. Cluster of Differentiation 47 (CD47), 
also known as the ‘don’t eat me signal’, aids in cell proliferation and evasion of phagocytosis 
and has been found to be a target for stopping tumorigenesis. Previous research has been 
successful in combining CD20 antibody blockades with an FDA approved drug called rituximab 
to improve survival in B cell non-Hodgkin lymphoma patients. While the success of this clinical 
trial is an optimistic outcome, there has not been any research done with using adjuvant drug 
therapy on solid tumor masses and CD47 targets. In my thesis, I will be identifying Imiquimod 
as a potential drug to rationally combine with B6H12 monoclonal antibodies for human 
colorectal cancer therapy as well as improving the methodology for conducting a phagocytosis 
assay by using luciferase. 
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INTRODUCTION 
 
Cancer treatment and management continues to be a prominent area of research for 
scientists because of the complex nature of the disease. Procedures such as chemotherapy, 
radiation therapy, and palliative care are all ways that have been found to eradicate or reduce the 
development of cancer. However, these treatments are far from being cures and many cancer 
cells are able to evade immune recognition and continue to proliferate within the body.  
With this in mind, research looking at ways to hijack the immune system for the benefit 
of the patient has been ongoing.  A critical advancement in the past couple of years has been the 
usage of targeted immunotherapy in oncological cases. The insurgence of immunotherapy 
research has opened up new perspectives on how to actively stop tumorigenesis using a patient’s 
own immune system as a self-vaccine. In using this methodology, the host’s immune system can 
eliminate unwanted malignant cells and reduce the amount of cancer cells evading 
immunosurveillance. So far, in the field of immunotherapy, the existing treatments range from 
activating effector immune cells with vaccination, going against inhibitory suppressive 
mechanisms, or neutralizing immune suppressor mechanisms. Antibodies have been extremely 
helpful in this as they can aid in reducing regulatory T cells and use them against 
immune-checkpoints. Prominent checkpoints that have been found to be critical in 
immunotherapy are CTLA-4 and PD1. CTLA-4 functions as a regulator of early immune 
response T-cell proliferation and PD1 functions in a later portion of the immune response in 
T-cell suppression (Rotte, 2019). These two checkpoints have proven to be incredibly essential 
in the process of tumorigenesis. Studies have evaluated that the combination of CTLA-4 and 
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PD-1 blockades increased response rates in metastatic melanoma patients and has increased 
efficacy in those cases. This study was critical in improving the prognosis of metastatic 
melanoma, advanced renal cell carcinoma and metastatic colorectal cancer patients in clinical 
trials and further in treatment (Rotte, 2019).  
 These strategies have paved an exciting new world of cancer immunotherapy and are 
advantageous to the race to cure cancer (Farkoma et al., 2016). With the identification of such 
checkpoints, more studies are being generated to find more checkpoints and functions that 
potentially can be blocked with monoclonal antibody therapy.  
 
Macrophage Mediated Phagocytosis of Cancer 
A process that has been largely impactful in the anti-tumorigenesis movement is 
phagocytosis. However, that process is considerably driven by inhibitory and stimulatory signals 
that could easily be disrupted by the tumor’s microenvironment and needs to be considered in 
any therapeutic advancements. The process of phagocytosis by macrophages is elicited by the 
innate immune response in the presence of a foreign pathogen. Macrophages are classified as 
effector cells that have the ability to discern between self and foreign agents through receptors 
built into its mechanism (Aderem et al., 1999). They also function to clear apoptotic cells and 
functions in the absence of inflammation. 
Aside from the tumor itself, the microenvironment plays a key role in tumorigenesis. The 
tumor’s microenvironment contains blood vessels, immune cells like macrophages, fibroblasts, 
signaling molecules, and lymphocytes that form a cellular environment that a tumor can survive 
in. With a combination of non-cancerous cells and cancer cells, the microenvironment is made to 
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sustain the many hallmarks that cancer exhibits. Typically, the non-malignant cells that are 
present in the microenvironment are tumor-promoting at all stages of oncogenic change.  
Although the tumor microenvironment has a vast number of different cell types and 
functions, it is a common understanding that each cell in that hypoxic environment contributes to 
the strong proliferation of tumor cells.  This poses a challenge because, with the aid of the 
microenvironment, cancer cells can evade many different types of processes like phagocytosis.  
Evasion is achieved by a cell surface glycoprotein that is found on many healthy cells in the 
body. CD47 is the inhibitory receptor responsible for this process. It is part of the 
immunoglobulin superfamily (Ig) and is expressed on tumor cell surfaces, allowing the cell to 
escape from immunosurveillance from macrophages and other effector cells. In addition to this, 
the high expression of CD47 on the surface of these tumors can also aid with furthering 
metastasis. With the possibility of exosomes being secreted with CD47 expression, tumors are 
given an easier access to the rest of the body and the tumor microenvironment is expanded (Lian 
et al., 2019).  
 
CD47 Blockade: A Therapeutic Target 
Current approaches in immunotherapy include research on CD47 as a promising 
immunotherapeutic target. Otherwise known as Cluster of Differentiation 47, CD47 is 
categorized under an immunoglobulin family (IgSF) and aids in cell functions like proliferation, 
adhesion, apoptosis, and most importantly, phagocytosis (Russ et al., 2018). Discovered 
originally as a plasma membrane molecule, CD47 is also part of the family of receptors for 
thrombospondin and is inhibitory in nature (Lian et al., 2019). It is expressed on normal cell 
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surfaces and found to be highly expressed on tumor cell and cancer stem cell surfaces (Kong et 
al., 2016). 
One of the main functions that CD47 takes on is what has been called a “Don’t Eat Me 
Signal” (Russ et al., 2018). When it is expressed on cell surfaces, CD47 functions as a ligand of 
signal regulatory protein-1 (SIRP-1), delivering an inhibitory signal to stop phagocytosis (Kong 
et al., 2016). SIRPα can be found on specific early hematopoietic progenitors of myeloid cells 
like macrophages. The specific binding of CD47 to SIRPα results in the phosphorylation of 
immunoreceptor tyrosine-based inhibition motifs which then triggers the recruitment of two 
phosphates: SHP1 and SHP2. These two phosphates inhibit myosin II from gathering at the 
phagocytic synapse and prevents phagocytosis from occurring (Russ et al., 2018). As the first 
phagocytosis checkpoint that researchers found in cancers, the CD47–SIRPα axis is important to 
continue to build upon (Feng et al., 2019). Studying this interaction can lead to more answers on 
how to prevent malignant cells from escaping immune cells like macrophages and also aid in 
preventing more migration and metastases in cancer patients. 
 
CD47-Sirpa Interaction 
The interaction between CD47 and SIRPα on macrophages is important because of its 
role in tumorigenesis. Macrophages are critical components of the innate immune system that 
recognize and eliminate any foreign pathogens that enter the body (Kong et al., 2016). They 
typically phagocytose foreign cells and avoid normal cells because SIRPα sits on the surface of 
macrophages. In normal cells, CD47 will be expressed and the macrophage will receive a 
negative signal telling it to ignore that cell and move on to the next. These immune checkpoints 
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are critical in cancer cell development and is one of the many reasons tumors can grow so 
rapidly. The binding of SIRP𝛼 with transmembrane protein CD47 establishes a signal 
transduction cascade which enables the obstruction of phagocytosis (Chao et al., 2010). 
Tumor cells have a characteristic ability to evade immunosurveillance. CD47 
overexpression has been found to be a major factor in why tumor cells are able to protect 
themselves from phagocytosis and contribute to the progression of tumor growth (Kong et al., 
2016). The abundance of CD47 expressed on tumor cell surfaces tricks macrophages into 
thinking that they are normal cells and therefore don’t need to be phagocytosed.  
Current research suggests that monoclonal antibodies (mAbs) are effective in aiding in 
tumor immunotherapy (Kong et al., 2016). B6H12 mAb is a monoclonal antibody that is able to 
interfere with the CD47 and SIRPα interaction because it is a specific anti-CD47 mAb. Recent 
studies have shown that anti-CD47 monoclonal antibodies eliminated selective tumor cells and 
evaded normal cells. Although the mechanism is not completely understood,  studies have found 
that the addition of anti-CD47 antibodies significantly changed the outcome for acute myeloid 
leukemia and tumors in the bladder by initiating phagocytosis on  leukemic stem cells and cancer 
stem cells, respectively (Kong et al., 2016).  
Immunotherapy and specifically targeting of CD47 are topics that have been researched 
in the past, but now we are interested in the possibilities of including adjuvant therapies to help 
speed up and increase the efficacy of the anti-CD47 blockades. One way to do this is to add an 
additional drug onto existing monoclonal antibody treatments. Prior research has found that the 
co-administration of rituximab, an  anti-CD20 antibody, and CD47-blocking antibody 
significantly inhibited the tumor growth in xenotransplanted models of human B cell 
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non-Hodgkin lymphoma in NSG mice and demonstrated a successful therapeutic effect (Feng et 
al., 2019). Other preclinical studies have also found similar effects with combination therapy 
with CD47-blocking antibodies in multiple different forms of cancers, such as anti-HER2 
antibody in breast cancer, anti-CD271 antibody in melanoma, and a handful more (Feng et al., 
2019). 
 
Imiquimod 
Imiquimod is an FDA approved drug that activates macrophages and cells through 
attachment to their cell surface receptors. In order to induce proinflammatory cytokine 
signalling, Imiquimod will bind to Toll-like receptor 7 and that process will signal the release of 
interferon (IFN)-a, interleukin (IL)-12, and tumor necrosis factor (TNF)-a (Stanley, 2002).  It has 
also been shown in previous studies that the presence of imiquimod plated ​in vitro ​with 
peripheral blood mononuclear cells, induced a release of interferon at high concentrations, 
making it an efficient inducer of cytokines (Stanley, 2002).  
Because macrophages hold such a central role in fighting tumorigenesis, the potential of 
enhancing their function with a TLR-7 agonist could be of great therapeutic value (Stanley, 
2002). From the clinical standpoint, Imiquimod has also been administered as a topical cream 
and has shown success with treatment of some basal cell carcinomas (Stanley, 2002). The 
combination of imiquimod as an adjuvant drug therapy could potentially increase the efficacy of 
monoclonal antibody defense in immunotherapy.  
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The usage of monoclonal antibody (mABs) as cancer therapy has been tested in a clinical 
trial focused on B cell non-Hodgkin lymphoma. In this study, they found a link between 
increased expression of CD47 in non-Hodgkin lymphoma cells and identified that as a predictor 
for negative clinical outcomes. They used rituximab, an anti-CD20 antibody, in their trials as it 
has been proven to significantly improve survival when used as a therapy for CD20-positive B 
cell lymphomas (Chao et al., 2010). Treatment with rituximab was successful in their study as 
they found that the antibody engaged with Fc receptors on effector cells, such as natural killer 
cells and macrophages, which in turn stimulates phagocytosis. The mechanism of blocking 
anti-CD47 antibodies increased the efficacy of the therapy. Future directions that emerge from 
this clinical trial find that this blockade created by mABs may be an effective modality for 
different forms of cancer therapy. Because malignancies can appear in a multitude of forms, 
starting to search for other therapeutic antibodies will be beneficial (Chao et al., 2010).  
Combining monoclonal antibodies in cancer therapy is worth studying further because of 
the positive outcomes it can achieve. This approach to cancer therapy reduces the toxicity rates 
of other therapy methods like chemotherapy and can increase the efficacy of the regimen.  
However, despite the success of Chao’s study, there are limitations that still need to be 
addressed. The study is primarily focused on non-Hodgkins lymphoma which is a form of liquid 
cancer or “blood cancer” and CD20 is specific to these types of B cell lymphomas. The efficacy 
of this sort of treatment on solid tumors has not been studied extensively and there is weak 
evidence of its efficacy.  
 
 
10 
Luciferase Assay 
Typically, GFP fluorescence screening and flow cytometry methods are used to count 
and sort large numbers of cells in experimental procedures. However, these methods are not 
adequate enough when it comes to working with live cancer cells and calculating phagocytosis 
rates. For one, these traditional methods are costive and highly labor intensive. They are also not 
high throughput screening friendly. In order to enhance transfection efficiency in cancer cells, a 
promoter is generally combined to a reporter gene which can be easily quantified in highly 
sensitive assays (Smale, 2010). A reporter gene that has proven to work well with sensitive 
assays is the luciferase gene. Derived from Photinus pyralis, a firefly, luciferin emits a 
fluorescent light product which can be easily quantified and measured. The specific mechanism 
that it utilizes is that it oxidizes D-luciferin in ATP, oxygen, and Mg(++) environments and its 
interaction with coenzyme A provides a channel for sustained light reaction (Smale, 2010). 
Phagocytosis assays are highly sensitive, fast-paced, and specific procedures and there needs to 
be a high throughput long term method to help it function at its best. Based on research, using a 
luciferase assay can enhance the accuracy and feasibility of live cancer cell data. Luciferase 
assays can function under rapid pace, are inexpensive compared to past methodologies, and are 
best suited for sensitive assay types.  
 
In my thesis, I will be studying the possibilities of rationally combining Imiquimod with 
CD47 monoclonal antibody blockades for human ​colorectal adenocarcinoma cancer ​therapy. As 
seen with previous clinical trials, adjuvant therapy is incredibly important in cancer treatment 
prognosis, and that is why it is increasingly important to study what ways targeted cancer antigen 
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specific regimens can be more refined.  In addition to improving the efficacy of monoclonal 
antibody treatment, some methodologies for identifying phagocytosis rates are not adequate 
enough. This thesis will also address a high throughput alternative to GFP signalling for yielding 
better results.  
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MATERIALS AND METHODS 
 
 
We looked for the efficacy of the drug Imiquimod in treating Colorectal Adenocarcinoma 
with human cell lines​ DLD1​ and​ SW480. ​Monoclonal antibodies B6H12 were used for the 
anti-CD47 blockades. Cells were harvested through trypsinization and washed using PBS. Cell 
lines were maintained at an incubation temperature of 37℃ and 5% CO​2​.​ ​Serial dilutions were 
performed 10 times from 2.3x10​6​ to have a 100 cell count in 6 mL medium (3 mL conditional 
medium and 3 mL fresh DMEM medium).  
 
Materials Preparation of Macrophages 
Macrophages were obtained through extracting bones from mice models. Bone marrow 
was collected through centrifugation and 5 mL of ACK buffer was used to wash the pellet of 
tissue cells. Solution was combined with FACs buffer and strained through a 70 µm cell strainer 
and centrifuged at 8000 rpm. The cells isolated from the bone marrow were plated on a six well 
plate with 2.5 mL IMDM medium mixed with 20µL dethawed MCSF (macrophage colony 
stimulating factor). Plates were incubated for 5 days at 37℃ and at 5% CO​2​. Additional 5µL 
MCSF was added on day four of incubation. Additional days of incubation were added if the 
differentiation of cells to macrophages was not enough. 
 
Improving Methodology for Identifying Phagocytosis Rates 
CMV-GFP-T2A-Luciferase Lentivector was used to infect cancer cell lines​ SW480​ and 
DLD1​. GFP-positive cells were isolated using flow cytometry 48 hours after initial infection. 
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Cells were read for GFP and luminescence signals with a BioTek Gen3 microplate reader and 
cell number was counted manually.  
 
 
Figure 1.​ Scheme of fluorescent versus luminescence tagging with the addition of macrophages, 
CD47 blockades (B6H12) over the course of 24 hours.  
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Quantifying Phagocytosis Rates in Cell Lines 
Visual analysis of a phagocytosis assay was done as a quick check for luminescence 
quality. Then, data from luciferin tagging with the addition of macrophages and B6 antibodies 
were compared to flow cytometry results through data analysis. A luciferase lentivector was 
added to colorectal adenocarcinoma cancer cell lines (​DLD1​ and ​SW480​). Macrophages (0.06 x 
10​6​ cells/well) and CD47 (B6H12) monoclonal antibody blockades at different concentrations (0, 
0.01, 0.1, 1, 0, 0 µg/ml) were also added for an infection period of 24 hours to a 24 well plate for 
the visual assay. With 5 columns included the addition of macrophages and one control column 
with just cancer cells. This was then run through a flow cytometry system and the data was 
compared to luminescence assay reading on ​a BioTek Gen3 microplate reader​. 
 
Screening of FDA Approved Drugs for Highest Phagocytosis Rate Change 
147 FDA approved anti-cancer small molecule drugs were screened and ranked. On day 
one, 5 μm of the drug compound with macrophage (0.06 x 10​6​ cells/well) and 0.6 M cancer cells 
with 1 mL mannose DMSO medium were added to 96 well plates. Each compound had two 
wells each for two conditions. One condition was with the addition of B6H12 (anti-CD47) 
antibody (0.02 µg/mg) and the other was a control without the antibody (Figure 2). Four 96-well 
plates were left to incubate for 24 hours at 37°C and 5% CO​2​. They were then read through ​the 
BioTek Gen3 microplate reader to analyse for final luminescence.  
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Figure 2​. Scheme detailing the process for screening of 147 FDA-approved drugs with 
anti-CD47 antibodies, macrophages, and ​DLD1 ​colorectal cancer cell lines.  
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RESULTS 
 
GFP signalling is typically used as a way to quantify cell numbers but in prior 
experiments, GFP signalling was found to emit a large amount of background noise which 
causes inaccuracies with reading live cancer cell signals. To find out if an alternative solution 
would improve the methodology for identifying phagocytosis rates, cancer cells were ​combined 
with luciferin, which is a luminescence signal, and GFP to see which signals were clearer and 
stronger. We wanted to find a high throughput compatible long-term phagocytosis assay. 
To test for this, we infected ​DLD1​ and​ SW480​ cancer cells with a lentivector containing 
both GFP and Luciferin. After 24 hours, the cells were sorted using flow cytometry and then 
manually counted. The results for after the GFP and Luciferin infected cells were separated show 
a difference in accuracy for signalling on cancer cell phagocytosis. In the graphs shown in Figure 
3, the two large figures depict fluorescence and luminescence intensity separately and show a 
similar data set with similar trendlines. However, when zoomed in, a more significant difference 
is seen. The magnified portion is a small sampling size of approximately 700 cell count versus 
the 240 x 10​3​ cell count. The data for GFP signalling at a small scale looks vastly different from 
its larger counterpart and shows a large amount of variation when there are less cells being 
evaluated. This is in comparison to the luciferase data which looks visually identical with less 
variation at large and small scale sample sizes. There is more validity in using a luminescence 
signal to quantify long-term phagocytosis based on the fact that luminescence signalling yields 
less variation and more accuracy when testing for small cell count size. It would be acceptable 
for GFP to be used as the method in which we test for phagocytosis in a large number of cancer 
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cells, but there is a significant loss of accuracy when presented with a small sample of cancer 
cells. Luminescence intensity is also measured at a higher quantity than in fluorescence. As 
shown in the graphs, luminescence intensity exceeds 35,000 which is around the maximum for 
the fluorescence intensity.  
 
 
Figure 3​. Fluorescence-GFP (right) and Luminescence-Luciferin (left) intensity assay on 
CMV-GFP-T2A-Luciferase Lentivector infected cancer cell lines ​SW480 ​(blue line) and ​DLD1 
(green line). Small graphs within the larger graphs indicate a smaller cell sampling size of 700 
cells. 
 
Following this, we wanted to visually establish the phagocytosis assay and make sure that 
luminescence would yield strong results when macrophages, anti-CD47 antibodies and cancer 
cells were all combined.  Different concentrations of B6H12 (anti-CD47 antibody) were added to 
each lane (0, 0.01, 0.1, 1, 0, 0 µg/ml) for two different cancer cell lines, ​DLD1 ​and ​SW480. ​Five 
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of the well columns had both macrophage and cancer cells mixed together, and one with just 
cancer cells as a control.​ ​ In Figure 4, there is a clear reduction of cancer cells when you include 
B6H12  in the wells which indicates the phagocytosis process with monoclonal antibodies is 
dose dependent. This can be seen by the stark difference between the dark blue and the bright 
colors in the cancer only control lane. The luminescence signal is strong in this phagocytosis 
assay, indicating that luminescence is a viable method and option to use in the rest of the 
experiment.  
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Figure 4.​ Phagocytosis assay check for luminescence validity. Macrophages (0.06 x 10​6 
cells/well) and 0.6 M cancer cells were added to well columns 1-5. In column 6, control with no 
macrophage and only cancer cells tested. CD47 (B6H12) monoclonal antibody blockades at 
differing concentrations (0, 0.01, 0.1, 0 and 0 µg/mL) were also added for an infection period of 
24 hours. Green and light blue luminescence indicated live cancer cell readings after 
phagocytosis, and dark blue indicates the cancer cells were phagocytosed within the time period. 
Column 6 with just cancer provides a reference for no phagocytosis over a 24 hour period.  
 
 
 
 
20 
To further assess the validity of the luminescence assay, the results were compared to an 
established methodology for phagocytosis assays. The luminescence assay data was compared to 
traditional flow cytometry (FACS) data. The cells were prepared in the same way and only the 
reading method was changed. Luminescence assay was found to return similar results to the 
traditional flow cytometry results. The phagocytosis indexes were compared in Figure 5 and the 
data points matched up with the y=x axis depicting a direct linear relationship and all data points 
fell between the error lines (light and dark purple lines). The error margins were ± 10%, which is 
a relatively small error margin with no stark outliers seen. This emphasizes the feasibility of this 
method as a long term phagocytosis assay because it is comparable to older methods.  
 
 
Figure 5. ​Comparison of​ ​flow cytometry data for phagocytosis in comparison to 
luminescence phagocytosis reading in cell lines (​SW480 and DLD1​) combined with Anti-CD47 
antibodies (​B6H12​) and bone marrow derived macrophages.  
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The final step of the experiment was to test 147 different FDA approved anticancer small 
molecule drugs to find a potential adjuvant drug to monoclonal antibody immunotherapy. Using 
DLD1 ​as our main cell line, we found that in screening all the FDA-approved drugs, imiquimod 
had the highest efficacy when plated with the monoclonal antibodies and the macrophages. Only 
the ​DLD1 ​cancer cell line was used for this experiment because screening of 147 drugs was time 
consuming and expensive. Imiquimod had the highest phagocytic index change at 60% of all the 
drugs that were tested. Each green dot on the graph represents each different drug that was tested 
(Figure 6). The phagocytic index change was calculated by taking the number of phagocytosed 
cells and dividing them by a normalized value. The normalized value was found by calculating 
the amount of cells in the control well as there is no phagocytosis taking place in those. An 
example calculation is as follows: for one compound, the normalized value with no antibody is 
100 and in the well with the compound and antibody, the value was 10 which yielded a 90% 
phagocytosis rate. This was then compared to a set of data in which mannose DMSO was used 
instead of the drug compound, and the phagocytosis rate for that was at a fixed 50%. The 
difference is then taken from those two values to get the phagocytosis index change amount, 
which in this example would be 40%. This is how we found a 60% index change for Imiquimod, 
indicating the efficiency of the drug in aiding in phagocytosis. Out of the 147 different drugs, 
half of them were found to have negative phagocytosis index change values as indicated by the 
green dots below the 0 line on the y-axis. This is because they were most likely helping with 
blocking phagocytosis. An example of why a compound would yield a negative phagocytosis 
index would be if the compound's phagocytosis rate is 10% and the difference between that and 
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the fixed 50% mannose DMSO value is -40%. Therefore, rather than enhancing phagocytosis, 
the compound induces anti-phagocytic effects instead. 
 
 
 
Figure 6. ​Testing of 147 FDA-approved anti-cancer small molecule drug compounds ranked for 
maximum efficacy in relation to phagocytosis index change. Drugs were only tested with the 
DLD1 ​human colorectal adenocarcinoma cell line.  Below the zero index change line (y-axis) are 
drug compounds that likely induce anti-phagocytic effects.  
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DISCUSSION AND CONCLUSION 
 
The increase in avenues of monoclonal antibody immunotherapy creates more 
possibilities for non-toxic treatment for cancer. The targeting of CD47 in the field of 
immunotherapy has increased over the past years and continues to stay that way because of the 
progress seen in the research. Identifying a drug with the potential to aid in anti-CD47 blockade 
functions without inducing additional toxic effects has become essential for the efficacy of the 
clinical treatments for specific cancers. Using monoclonal antibody immunotherapy exclusively 
is not adequate enough for the eradication of a fast developing and unpredictable disease.  
It was discussed in the earlier sections of this thesis that there are currently two major 
limitations regarding research on utilizing CD47 blockades as agents of immunotherapy that we 
wanted to focus on. The first major limitation was that the effects of targeted CD47 
immunotherapy on solid tumor cases had not been proven as a success as of yet because only 
liquid type cancers (B cell non-Hodgkin's Lymphoma) had been tested extensively. In this 
experiment, we found that in addition to the combination of anti-CD47 antibodies (B6H12) and 
anti-SIRPα antibodies (P84), imiquimod as an adjuvant drug treatment can increase the efficacy 
of this cancer therapy based on it’s phagocytic index change amount. Based on the results of our 
147 FDA-approved anticancer small molecule drug screen, the difference between when 
imiquimod was added and when mannose DMSO was added showed a 60% increase in 
phagocytosis rates. This was the highest amount of all the drugs screened. We found this by 
specifically testing in human colorectal adenocarcinoma cancer cell lines ​DLD1​ as they are 
representative of solid tumor cancers.  
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The second limitation was that GFP signalling provided far too disruptive results because 
of the background noise and light emitted in the screening. In this experiment we were able to 
find an alternative solution to that through the usage of luciferin as a tagging signal and found 
that it drastically improved our outcomes. We found that GFP signalling was accurate at large 
scale cell counts but when we tested for cell numbers in the hundreds, the signals were disruptive 
and highly variable. For Luciferase signalling, the results were similar and not variable at both 
small and large scale cell counts. We verified our findings through both a visual screening of the 
efficacy when plated with anti-CD47 antibodies and through traditional FACS sorting. Our 
proposed method of using Luciferase proved to be more efficient than GFP signalling in 
phagocytosis assay experiments. Using this luminescence approach would provide more accurate 
results with less background noise or light signals when working with small sample sizes.  
A large quantity of drugs were tested in the search for the best adjuvant treatment for 
monoclonal antibody immunotherapy and imiquimod came out as a top contender in ​DLD1 ​cell 
lines. Now that we have sufficient data for the ranking of the compounds, we no longer need to 
test for all 147 drugs in solid tumor cell lines. We can immediately eliminate those that elicited a 
negative phagocytosis index range number and focus on either the top five found in the 
experiment, or any of the drugs found above the line. This way, we can do further testing on 
other cell lines like ​SW480 ​or other solid tumor cell lines to identify whether or not it is entirely 
accurate or if those specific drugs work on just human colorectal adenocarcinoma cancer cell 
lines. 
Potential weaknesses of this study was that we were only able to test these drugs in ​DLD1 
cancer cell lines. It is more than possible that imiquimod is only feasible and effective in this cell 
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line based on its mechanisms. However, this is not something that we can assure until more 
testing is done on other cell lines and models. Another potential weakness for where this study 
could go is based more on previous findings and is a potential weakness for anti-CD47 therapy in 
general. There are concerns that xenograft hosts can underestimate the effects of anti-CD47 
therapy because of specific reagents in mice models that affect CD47 clustering and also the 
interaction of CD47-​SIRPα​ (Huang, 2017). We may not be able to truly test the efficiency of 
imiquimod as an adjuvant drug until a more certain xenograft model is created. We have no idea 
of how imiquimod would work in vivo if the CD47 interactions in a different species could be 
variably different from human processes. 
However, because of the success of Chao’s findings with​ Rituximab​ and anti-CD20 
antibodies, hopefully this study can further the studies into solid tumor treatments in the future. 
The clinical trials for B cell non-Hodgkin’s lymphoma have been successful in its goals and 
these findings could potentially open up more avenues to increase the efficacy of treatment in 
both liquid and solid tumor cancers. 
There are however concerns on the direction in which monoclonal antibody therapy will 
take in the future. It is important to clarify that there is much more research needed to be done in 
order for this finding to be significant. For example, because xenograft mice models are different 
in composition from humans, much more additional research will have to be done on how to 
precisely determine validity in in-vivo testing. Another concern would be, since CD47 is present 
in all normal cells, would monoclonal antibody treatment affect the normal cells in the body? 
Imiquimod would most certainly help guide macrophages in targeting cancer cells over normal 
cells, but it would not be surprising if normal cells that surround the tumor microenvironment 
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would be affected as well, maybe also eliciting an unwanted immune response. It is important 
that more research goes into specific things like that, and figuring out methods in which only the 
tumor is targeted in therapy. The point of immunotherapy is to reduce toxic effects to the rest of 
the body. In order for monoclonal antibody therapy to be the better option or the more effective 
option, these safety concerns must be addressed.  
In conclusion, we were able to improve the methodology of conducting phagocytosis 
assays by comparing GFP fluorescent signalling to our proposed alternative which is 
luminescence signalling with luciferase. We were able to verify our luciferase assay for 
phagocytosis rate accuracy using flow cytometry and a visual check, and finally we screened 
FDA approved drugs for highest phagocytosis rate change and found that Imiquimod would 
yield the highest efficacy. The identification of imiquimod as a potential combination for 
anti-CD47 antibodies in cancer therapy provides a stepping stone for future studies on creating a 
treatment modality for cancer that is less toxic and life quality reducing. Through searching for 
more potential adjuvant drug combinations as well as more immunological targets, 
improvements to life quality and disease prognosis can increase positively. 
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